Results

1–7 of 7 results for intravitreal implant

The Effect of Baseline Ellipsoid Zone-Area Loss on Treatment Response of Revakinagene Taroretcel (NT-501) in Macular Telangiectasia Type 2
Sophie Jane Bakri, MD
Annual Meeting Talks
2025
PER-001, a Long-acting Endothelin Antagonist Intravitreal Implant, Improved Structure and Visual Function in Patients With Diabetic Retinopathy
Justis P. Ehlers, MD, FASRS
Annual Meeting Talks
2025
Fluocinolone Intravitreal Implant in Patients With Macular Edema Due to Retinal Vein Occlusion
Ashkan M. Abbey, MD, FASRS, FAAO
On Demand Cases, Courses, and Papers
2021
Characteristics and the Need for Supplementation Following 0.19mg Fluocinolone Acetonide (FAc) in Diabetic Macular Edema (DME) Patients
Victor Hugo Gonzalez, MD
Annual Meeting Talks
2021
Best Corrected Visual Acuity (BCVA) and Central Macular Thickness (MAT) Outcomes After Fluocinolone Acetonide Intravitreal Implant Injection
Dana M. Deupree, MD
Annual Meeting Talks
2018
One-Year Results of Fluocinolone Acetonide Intravitreal Implant For Diabetic Macular Edema in Highly Treated Eyes
Sumit P. Shah, MD, FACS, FASRS
On Demand Cases, Courses, and Papers
2017
Vasoproliferative Tumor With Resultant Total Exudative RD Status Post Vitrectomy/Laser/Oil/Dexamethasone Intravitreal Implant
Christopher G Fuller, MD
Retina Image Bank: Images of the Week
2017